Redistribution of accumulated cell iron: A modality of chelation with therapeutic implications

Blood

Volumn 111, Issue 3, 2008, Pages 1690-1699

  Sohn, Yang Sung ^a   Breuer, William ^a   Munnich, Arnold ^b   Cabantchik, Z Ioav ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b Clinique de Genetique Medicale   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERIPRONE; IRON; TRANSFERRIN;

ANEMIA; ANIMAL CELL; ARTICLE; CELL COMPARTMENTALIZATION; CELLULAR DISTRIBUTION; FLUORESCENCE MICROSCOPY; HEMOGLOBIN SYNTHESIS; IN VIVO STUDY; IRON CHELATION; IRON TRANSPORT; MITOCHONDRION; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 38949197818     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-07-102335     Document Type: Article

References (49)

1. Hershko C, Link G, Konijn AM, Cabantchik ZI. Objectives and mechanism of iron chelation therapy. Ann N Y Acad Sci. 2005;1054:124-135.
2. Hershko C, Cappellini MD, Galanello R, Piga A, Tognoni G, Masera G. Purging iron from the heart. Br J Haematol. 2004;125:545-551.
3. Napier I, Ponka P, Richardson DR. Iron trafficking in the mitochondrion: novel pathways revealed by disease. Blood. 2005;105:1867-1874.
4. Wilson RB. Iron dysregulation in Friedreich ataxia. Semin Pediatr Neurol. 2006;13:166-175.
5. Hayflick SJ. Neurodegeneration with brain iron accumulation: from genes to pathogenesis. Semin Pediatr Neurol. 2006;13:182-185.
6. Gregory A, Hayflick SJ. Neurodegeneration with brain iron accumulation. Folia Neuropathol. 2005;43:286-296.
7. Ganz T. Molecular pathogenesis of anemia of chronic disease. Pediatr Blood Cancer. 2006;46:554-557.
8. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood. 2003;102:783-788.
9. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352:1011-1023.
10. Liu ZD, Hider RC. Iron chelator chemistry. In Templeton DM, ed. Molecular and Cellular Iron Transport. New York, NY: Marcel Dekker; 2002:321-357.
11. Breuer W, Ermers MJ, Pootrakul P, Abramov A, Hershko C, Cabantchik ZI. Desferrioxamine-chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapy. Blood. 2001;97:792-798.
12. Evans RW, Sharma M, Ogwang W, Patel KJ, Bartlett AN, Kontoghiorghes GJ. The effect of alpha-ketohydroxypyridine chelators on transferrin saturation in vitro and in vivo. Drugs Today (Barc). 1992;28:19-23.
13. Boddaert N, Le Quan Sang KH, Rötig A, et al. Selective iron chelation in Friedreich ataxia. Biological and clinical implications. Blood. 2007;110:401-408.
14. Waldmeier PC, Buchle AM, Steulet AF. Inhibition of catechol-O- methyltransferase (COMT) as well as tyrosine and tryptophan hydroxylase by the orally active iron chelator, 1,2-dimethyl-3-hydroxypyridin-4-one (L1, CP20), in rat brain in vivo. Biochem Pharmacol. 1993;45:2417-2424.
15. Habgood MD, Liu ZD, Dehkordi LS, Khodr HH, Abbott J, Hider RC. Investigation into the correlation between the structure of hydroxypyridinones and blood-brain barrier permeability. Biochem Pharmacol. 1999;57:1305-1310.
16. Fredenburg AM, Sethi RK, Allen DD, Yokel RA. The pharmacokinetics and blood-brain barrier permeation of the chelators 1,2 dimethly-, 1,2 diethyl-, and 1-[ethan-1′ol]-2-methyl-3-hydroxypyridin-4-one in the rat. Toxicology. 1996;108:191-199.
17. Harris WR. Iron chemistry. In Templeton DM, ed. Molecular and Cellular Iron Transport. New York, NY: Marcel Dekker; 2002;1-40.
18. Thomas F, Serratrice G, Beguin C, et al. Calcein as a fluorescent probe for ferric iron. Application to iron nutrition in plant cells. J Biol Chem. 1999;274:13375- 13383.
19. Singh S, Hider RC, Porter JB. A direct method for quantification of non-transferrin-bound iron. Anal Biochem. 1990;186:320-323.
20. Glickstein H, Ben El R, Shvartsman M, Cabantchik ZI. Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells. Blood. 2005;106:3242-3250.
21. Glickstein H, Ben El R, Link G, et al. Action of chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequences. Blood. 2006;108:3195-3203.
22. Petrat F, Weisheit D, Lensen M, de Groot H, Sustmann R, Rauen U. Selective determination of mitochondrial chelatable iron in viable cells with a new fluorescent sensor. Biochem J. 2002;362:137-147.
23. Shvartsman M, Kikkeri R, Shanzer A, Cabantchik IZ. Non-transferrin-bound iron reaches mitochondria by a chelator-inaccessible mechanism: biological and clinical implications. Am J Physiol Cell Physiol. 2007;293:C1383-C1394.
24. Haberland A, Bottger M. Nuclear proteins as gene-transfer vectors. Biotechnol Appl Biochem. 2005;42:97-106.
25. He QY, Mason AB, Lyons BA, et al. Spectral and metal binding properties of three single-point tryptophan mutants of the human transferring N-lobe. Biochem J. 2001;354:423-429.
26. Marks PA, Rifkind RA. Hexamethylene bis-acetamide-induced differentiation of transformed cells: molecular and cellular effects and therapeutic application. Int J Cell Cloning. 1988;6:230-240.
27. Alcantara O, Boldt DH. Iron deprivation blocks multilineage haematopoietic differentiation by inhibiting induction of p21(WAF1/CIP1). Br J Haematol. 2007;137:252-261.
28. Huebers HA, Eng MJ, Josephson BM, et al. Plasma iron and transferrin iron-binding capacity evaluated by colorimetric and immunoprecipitation methods. Clin Chem. 1987;33:273-277.
29. Bradbury MW. Transport of iron in the blood-brain-cerebrospinal fluid system. J Neurochem. 1997;69:443-454.
30. Moos T, Morgan EH. Evidence for low molecular weight, non-transferrin-bound iron in rat brain and cerebrospinal fluid. J Neurosci Res. 1998;54:486-494.
31. Theurl I, Mattle V, Seifert M, Mariani M, Marth C, Weiss G. Dysregulated monocyte iron homeostasis and erythropoietin formation in patients with anemia of chronic disease. Blood. 2006;107:4142-4148.
32. Kontoghiorghes GJ. New concepts of iron and aluminium chelation therapy with oral L1 (deferiprone) and other chelators. Analyst. 1995;120:845-851.
33. Whitnall M, Richardson DR. Iron: a new target for pharmacological intervention in neurodegenerative diseases. Semin Pediatr Neurol. 2006;13:186-197.
34. Berg D, Youdim MB. Role of iron in neurodegenerative disorders. Top Magn Reson Imaging. 2006;17:5-17.
35. Rouault TA, Cooperman S. Brain iron metabolism. Semin Pediatr Neurol. 2006;13:142-148.
36. Zanninelli G, Glickstein H, Breuer W, et al. Chelation and mobilization of cellular iron by different classes of chelators. Mol Pharmacol. 1997;51:842-852.
37. Link G, Konijn AM, Breuer W, Cabantchik ZI, Hershko C. Exploring the "iron shuttle" hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture. J Lab Clin Med. 2001;138:130-138.
38. Breuer W, Shvartsman M, Cabantchik ZI. Intracellular labile iron. Int J Biochem Cell Biol. Prepublished on March 19, 2007, as DOI 10.1016/j.biocel.2007. 03.010.
39. Kruszewski M. Labile iron pool: The main determinant of cellular response to oxidative stress. Mutat Res. 2003;29:81-92.
40. Espósito BP, Epsztejn S, Breuer W, Cabantchik ZI. A review of fluorescence methods for assessing labile iron in cells and biological fluids. Anal Biochem. 2002;304:1-18.
41. Aisen P, Listowsky I. Iron transport and storage proteins. Annu Rev Biochem. 1980;49:357-393.
42. Devanur LD, Neubert H, Hider RC. The Fenton activity of iron(III) in the presence of deferiprone. J Pharm Sci. Prepublished August 27, 2007, as DOI 10.1002/jps.21039.
43. Garrick LM, Gniecko K, Hoke JE, al-Nakeeb A, Ponka P, Garrick MD. Ferric-salicylaldehyde isonicotinoyl hydrazone, a synthetic iron chelate, alleviates defective iron utilization by reticulocytes of the Belgrade rat. J Cell Physiol. 1991;146:460-465.
44. Singh S, Khodr H, Taylor MI, Hider RC. Therapeutic iron chelators and their potential side-effects. Biochem Soc Symp. 1995;61:127-137.
45. Esposito BP, Breuer W, Sirankapracha P, Pootrakul P, Hershko C, Cabantchik ZI. Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood. 2003;102:2670-2677.
46. Ludwiczek S, Aigner E, Theurl I, Weiss G. Cytokine-mediated regulation of iron transport in human monocytic cells. Blood. 2003;101:4148-4154.
47. Vreugdenhil G, Swaak AJ, de Jeu-Jaspers C, van Eijk HG. Correlation of iron exchange between the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4- one(L1) and transferrin and possible antianaemic effects of L1 in rheumatoid arthritis. Ann Rheum Dis. 1990;49:956-957.
48. Spivak JL. Iron and the anemia of chronic disease. Oncology (Williston Park). 2002;16:Suppl 10:25-33.
49. Vreugdenhil G, Swaak AJ, Kontoghiorghes GJ, van Eijk HG. Efficacy and safety of oral iron chelator L1 in anaemic rheumatoid arthritis patients [letter]. Lancet. 1989;2:1398-1399.